Thomas Catinazzo sold $268k of RLAY
Chief Financial Officer at Relay Therapeutics, Inc.. 58,936 shares at an average of $4.55, traded Jan 28, 2025, filed Jan 30, 2025.
Score components
- +22RoleCFO
- +13Trade size$268k at market
- +5Share of holdings soldSold 20% of holdings
- +15Cluster3 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-011327, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 28, 2025 | SOpen-market sale Common Stock10b5-1 | -33,753 | $4.63 | $156k | 265,473 | Jan 30, 2025 |
| Jan 28, 2025 | SOpen-market sale Common Stock10b5-1 | -2,283 | $4.63 | $11k | 263,190 | Jan 30, 2025 |
| Jan 28, 2025 | AGrant or award Common Stock10b5-1 | +139,141 | $0.00 | $0 | 402,331 | Jan 30, 2025 |
| Jan 29, 2025 | SOpen-market sale Common Stock10b5-1 | -2,109 | $4.55 | $9,596 | 400,222 | Jan 30, 2025 |
| Jan 30, 2025 | SOpen-market sale Common Stock10b5-1 | -20,791 | $4.42 | $92k | 379,431 | Jan 30, 2025 |
Related signals
Other insiders at Relay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $329k 17,717 shares | -14% | |
| 36Weak | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $872k 48,199 shares | -9% | |
| 26Weak | Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $162k 8,530 shares | -2% | |
| 37Weak | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $336k 17,717 shares | -13% | |
| 44Moderate | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $913k 48,199 shares | -8% | |
| 31Weak | RLAYsell Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $167k 21,581 shares | -5% | |
| 57Moderate | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $435k 62,073 shares | -8% | |
| 48Moderate | Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $225k 30,897 shares | -6% | |
| 48Moderate | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $158k 21,664 shares | -6% | |
| 49Moderate | Relay Therapeutics, Inc. | Peter Rahmer See remarks | $300k 40,529 shares | -11% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.